Drug intelligence / Profile preview

AM-1004

Development stage: Preclinical
Lead developer: Arcadia Medicine
Modality: Small Molecules

Overview

**AM-1004** is an Arcadia Medicine preclinical neuropsychiatric drug candidate being developed for **major depressive disorder**. Arcadia describes it as a short-acting psychoactive empathogen combination therapy intended to provide an improved therapeutic profile; a company press release further characterizes it as a mildly entactogenic antidepressant designed for self-administration as a potential alternative to SSRIs and SNRIs. Its molecular structure, individual active components, and precise receptor-level pharmacology have not been publicly disclosed. ([arcadiamedicine.com](https://arcadiamedicine.com/))

Beyond the preview

Go deeper on AM-1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-1004.

Explore the full profile